|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TASOR2 |
Gene summary for TASOR2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TASOR2 | Gene ID | 54906 |
| Gene name | transcription activation suppressor family member 2 | |
| Gene Alias | C10orf18 | |
| Cytomap | 10p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5VWN6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54906 | TASOR2 | CCI_2 | Human | Cervix | CC | 7.97e-15 | 1.45e+00 | 0.5249 |
| 54906 | TASOR2 | CCI_3 | Human | Cervix | CC | 1.08e-07 | 8.76e-01 | 0.516 |
| 54906 | TASOR2 | Tumor | Human | Cervix | CC | 1.81e-04 | -2.16e-01 | 0.1241 |
| 54906 | TASOR2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.23e-04 | 1.44e-01 | 0.0155 |
| 54906 | TASOR2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.42e-05 | 1.71e-01 | -0.1808 |
| 54906 | TASOR2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.23e-05 | 2.21e-01 | -0.0811 |
| 54906 | TASOR2 | HTA11_78_2000001011 | Human | Colorectum | AD | 7.82e-22 | 5.45e-01 | -0.1088 |
| 54906 | TASOR2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.50e-55 | 8.46e-01 | -0.1954 |
| 54906 | TASOR2 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.86e-06 | 5.05e-01 | -0.2602 |
| 54906 | TASOR2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.29e-05 | 3.37e-01 | -0.2196 |
| 54906 | TASOR2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.57e-06 | 2.13e-01 | -0.1207 |
| 54906 | TASOR2 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.83e-15 | 4.54e-01 | -0.1526 |
| 54906 | TASOR2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.19e-14 | 2.94e-01 | -0.1464 |
| 54906 | TASOR2 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.09e-16 | 3.48e-01 | -0.1001 |
| 54906 | TASOR2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.86e-22 | 5.87e-01 | -0.059 |
| 54906 | TASOR2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.14e-07 | 3.33e-01 | -0.1706 |
| 54906 | TASOR2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.40e-02 | 1.93e-01 | -0.1462 |
| 54906 | TASOR2 | HTA11_546_2000001011 | Human | Colorectum | AD | 2.42e-10 | 4.42e-01 | -0.0842 |
| 54906 | TASOR2 | HTA11_9341_2000001011 | Human | Colorectum | SER | 4.01e-04 | 4.03e-01 | -0.00410000000000005 |
| 54906 | TASOR2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.24e-02 | 1.79e-01 | -0.0179 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |